These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 25635138)

  • 1. Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.
    Yu EY; Duan F; Muzi M; Deng X; Chin BB; Alumkal JJ; Taplin ME; Taub JM; Herman B; Higano CS; Doot RK; Hartfeil D; Febbo PG; Mankoff DA
    J Nucl Med; 2015 Mar; 56(3):354-60. PubMed ID: 25635138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-Body [
    Muzi M; O'Sullivan F; Perk TG; Muzi JP; Mankoff DA; Jeraj R; Duan F; Yu EY
    Tomography; 2021 Apr; 7(2):139-153. PubMed ID: 33923126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival.
    Etchebehere EC; Araujo JC; Fox PS; Swanston NM; Macapinlac HA; Rohren EM
    J Nucl Med; 2015 Aug; 56(8):1177-84. PubMed ID: 26069307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative Assessment of Early [
    Harmon SA; Perk T; Lin C; Eickhoff J; Choyke PL; Dahut WL; Apolo AB; Humm JL; Larson SM; Morris MJ; Liu G; Jeraj R
    J Clin Oncol; 2017 Aug; 35(24):2829-2837. PubMed ID: 28654366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Anatomic Location of Bone Metastases on Prognosis in Metastatic Castration-Resistant Prostate Cancer.
    Roth AR; Harmon SA; Perk TG; Eickhoff J; Choyke PL; Kurdziel KA; Dahut WL; Apolo AB; Morris MJ; Perlman SB; Liu G; Jeraj R
    Clin Genitourin Cancer; 2019 Aug; 17(4):306-314. PubMed ID: 31221545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases.
    Donners R; Tunariu N; Tovey H; Hall E; Chua S; Cook G; Du Y; Blackledge MD; Parker CC; Koh DM
    Eur Radiol; 2024 Feb; 34(2):1146-1154. PubMed ID: 37615760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uptake of Radium-223 Dichloride and Early [
    Letellier A; Johnson AC; Kit NH; Savigny JF; Batalla A; Parienti JJ; Aide N
    Mol Imaging Biol; 2018 Jun; 20(3):482-491. PubMed ID: 29027074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.
    Twardowski PW; Beumer JH; Chen CS; Kraft AS; Chatta GS; Mitsuhashi M; Ye W; Christner SM; Lilly MB
    Anticancer Drugs; 2013 Aug; 24(7):743-53. PubMed ID: 23652277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic analysis of 18F-fluoride PET images of breast cancer bone metastases.
    Doot RK; Muzi M; Peterson LM; Schubert EK; Gralow JR; Specht JM; Mankoff DA
    J Nucl Med; 2010 Apr; 51(4):521-7. PubMed ID: 20237040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer.
    Yu EY; Wilding G; Posadas E; Gross M; Culine S; Massard C; Morris MJ; Hudes G; Calabrò F; Cheng S; Trudel GC; Paliwal P; Sternberg CN
    Clin Cancer Res; 2009 Dec; 15(23):7421-8. PubMed ID: 19920114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers.
    Maines F; Caffo O; Donner D; Sperduti I; Bria E; Veccia A; Chierichetti F; Tortora G; Galligioni E
    Future Oncol; 2016 Feb; 12(3):333-42. PubMed ID: 26768648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
    Hanyok BT; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Posadas EM; Freedland SJ
    Cancer; 2016 Jan; 122(2):222-9. PubMed ID: 26484853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Pilot Trial Evaluating Zoledronic Acid Induced Changes in [
    Vaishampayan UN; Tehrani OS; Lawhorn-Crews JM; Heilbrun LK; Dobson K; Smith D; Dickow B; Shields AF
    Mol Imaging Biol; 2017 Dec; 19(6):810-816. PubMed ID: 28289967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring Spatial-Temporal Changes in
    Kyriakopoulos CE; Heath EI; Ferrari A; Sperger JM; Singh A; Perlman SB; Roth AR; Perk TG; Modelska K; Porcari A; Duggan W; Lang JM; Jeraj R; Liu G
    J Clin Oncol; 2020 Nov; 38(31):3662-3671. PubMed ID: 32897830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-body 18F-fluorocholine (FCH) PET/CT and MRI of the spine for monitoring patients with castration-resistant prostate cancer metastatic to bone: a pilot study.
    Balogova S; Zakoun JB; Michaud L; Khalil A; Tassart M; Esteso A; Kerrou K; Huchet V; Carette MF; Lotz JP; Talbot JN
    Clin Nucl Med; 2014 Nov; 39(11):951-9. PubMed ID: 25140552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer.
    Vaishampayan UN; Podgorski I; Heilbrun LK; Lawhorn-Crews JM; Dobson KC; Boerner J; Stark K; Smith DW; Heath EI; Fontana JA; Shields AF
    Clin Cancer Res; 2019 Jan; 25(2):652-662. PubMed ID: 30327304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
    Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I
    J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.
    Spreafico A; Chi KN; Sridhar SS; Smith DC; Carducci MA; Kavsak P; Wong TS; Wang L; Ivy SP; Mukherjee SD; Kollmannsberger CK; Sukhai MA; Takebe N; Kamel-Reid S; Siu LL; Hotte SJ
    Invest New Drugs; 2014 Oct; 32(5):1005-16. PubMed ID: 24788563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing an 18F-NaF and 18F-FDG cocktail for PET assessment of metastatic castration-resistant prostate cancer.
    Simoncic U; Perlman S; Liu G; Jeraj R
    Nucl Med Commun; 2015 Dec; 36(12):1174-80. PubMed ID: 26378490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer.
    Rowe SP; Macura KJ; Ciarallo A; Mena E; Blackford A; Nadal R; Antonarakis ES; Eisenberger MA; Carducci MA; Ross AE; Kantoff PW; Holt DP; Dannals RF; Mease RC; Pomper MG; Cho SY
    J Nucl Med; 2016 Jan; 57(1):46-53. PubMed ID: 26493203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.